MSON / Misonix Inc - Документы SEC, Годовой отчет, Доверенное заявление

Misonix, LLC 1938 New Highway Farmingdale, New York 11735 (631) 694-9555

Misonix, LLC 1938 New Highway Farmingdale, New York 11735 (631) 694-9555 November 22, 2021 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Re: Withdrawal of Misonix, Inc.

As filed with the Securities and Exchange Commission on November 8, 2021 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXC

As filed with the Securities and Exchange Commission on November 8, 2021 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

As filed with the Securities and Exchange Commission on October 29, 2021

As filed with the Securities and Exchange Commission on October 29, 2021 Registration No.

As filed with the Securities and Exchange Commission on October 29, 2021

As filed with the Securities and Exchange Commission on October 29, 2021 Registration No.

As filed with the Securities and Exchange Commission on October 29, 2021

As filed with the Securities and Exchange Commission on October 29, 2021 Registration No.

As filed with the Securities and Exchange Commission on October 29, 2021

As filed with the Securities and Exchange Commission on October 29, 2021 Registration No.

As filed with the Securities and Exchange Commission on October 29, 2021

As filed with the Securities and Exchange Commission on October 29, 2021 Registration No.

As filed with the Securities and Exchange Commission on October 29, 2021

As filed with the Securities and Exchange Commission on October 29, 2021 Registration No.

As filed with the Securities and Exchange Commission on October 29, 2021

As filed with the Securities and Exchange Commission on October 29, 2021 Registration No.

Limited Liability Company Agreement of Misonix, LLC

Exhibit 3.2 AMENDED AND RESTATED LIMITED LIABILITY COMPANY AGREEMENT of MISONIX, LLC This AMENDED AND RESTATED LIMITED LIABILITY COMPANY AGREEMENT (this ?Agreement?) has been adopted by Bioventus Inc., a Delaware corporation, as the sole member (the ?Member?) of Misonix, LLC, a Delaware limited liability company (f/k/a Oyster Merger Sub II, LLC; the ?Company?), effective as of October 29, 2021. WH

Certificate of Formation of Merger Sub II

Exhibit 3.1 CERTIFICATE OF FORMATION OF OYSTER MERGER SUB II, LLC Dated as of July 27, 2021 This Certificate of Formation of Oyster Merger Sub II, LLC is being duly executed and filed by the undersigned, as an authorized person, to form a limited liability company under the Delaware Limited Liability Company Act (6 Del. C. ? 18-101, et seq.). 1. Name. The name of the limited liability company form

Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Termination of a Material Definitive Agreement, Material Modification to Rights of Security Holders, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2021 MISONIX, INC. (by Misonix, LLC, as successor by merger to Misonix, Inc.) (Exact name of registrant as specified in its charter) Delaware 001-10986 84-1856018 (State o

As filed with the Securities and Exchange Commission on October 29, 2021

As filed with the Securities and Exchange Commission on October 29, 2021 Registration No.

As filed with the Securities and Exchange Commission on October 29, 2021

As filed with the Securities and Exchange Commission on October 29, 2021 Registration No.

As filed with the Securities and Exchange Commission on October 29, 2021

As filed with the Securities and Exchange Commission on October 29, 2021 Registration No.

Bioventus and Misonix Stockholders Approve the Acquisition of Misonix by Bioventus

Exhibit 99.1 Bioventus and Misonix Stockholders Approve the Acquisition of Misonix by Bioventus DURHAM, NC and FARMINGDALE, NY ? October 26, 2021 ? Bioventus Inc. (Nasdaq: BVS) (?Bioventus? or the ?Company?), a global leader in innovations for active healing, and Misonix, Inc. (Nasdaq: MSON) (?Misonix?), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine

Regulation FD Disclosure, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2021 MISONIX, INC. (Exact name of registrant as specified in its charter) Delaware 001-10986 84-1856018 (State or other jurisdiction of incorporation) (Commission File Num

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 18, 2021 MISONIX, INC. (Exact name of Registrant as specified in its charter) Delaware 001-10986 84-1856018 (State or Other Jurisdiction of Incorporation) (Commission File Num

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 18, 2021 MISONIX, INC. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 18, 2021 MISONIX, INC. (Exact name of Registrant as specified in its charter) Delaware 001-10986 84-1856018 (State or Other Jurisdiction of Incorporation) (Commission File Num

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 18, 2021 BIOVENTUS INC. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 18, 2021 BIOVENTUS INC. (Exact name of Registrant as specified in its charter) Delaware 001-37844 81-0980861 (State or Other Jurisdiction of Incorporation) (Commission File Nu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section14(a) of the Securities Exchange Act of 1934

DEFM14A 1 d198229ddefm14a.htm DEFM14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as

Filed by Misonix, Inc.

Filed by Misonix, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Misonix, Inc. Commission File No.: 001-10986 Goal of Internal Communications by Misonix 1. Create unified voice, position and messages consistent at all levels of the company. 2. Keep Misonix employees engaged and focused o

10.11 Misonix, Inc. Executive Annual Bonus Incentive Plan Description

Exhibit 10.11 Misonix, Inc. Description of Executive Annual Bonus Incentive Plan On July 26, 2021, the Compensation Committee (the ?Committee?) of the Board of Directors of Misonix, Inc. (the ?Company?), approved the terms and conditions of the Company?s fiscal year 2022 annual cash incentive plan (the ?2022 Plan?) for certain officers of the Company, including certain of the Company?s named execu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2021 ☐ TRANSITION REPORT PURSUANT TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2021 -06-30 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-10986 MISONIX, INC.

MISONIX REPORTS FOURTH QUARTER AND FISCAL YEAR 2021 FINANCIAL RESULTS

Exhibit 99.1 Draft V5 For Immediate Release News Announcement MISONIX REPORTS FOURTH QUARTER AND FISCAL YEAR 2021 FINANCIAL RESULTS FARMINGDALE, N.Y., September 2, 2021 ? Misonix, Inc. (Nasdaq: MSON) (?Misonix? or the ?Company?), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today reported unaudited financial resul

Subsidiaries of the Registrant

Exhibit 21.1 Subsidiaries of Misonix, Inc. Name of Subsidiary Jurisdiction of Incorporation Misonix OpCo, Inc. New York Solsys Medical, LLC Delaware

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 2, 2021 MISONIX, INC. (

425 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 2, 2021 MISONIX, INC. (Exact name of Registrant as specified in its charter) Delaware 001-10986 84-1856018 (State or Other Jurisdiction (Commission (IRS Em

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 2, 2021 MISONIX, INC. (Exact name of Registrant as specified in its charter) Delaware 001-10986 84-1856018 (State or Other Jurisdiction (Commission (IRS Employer of Incorpor

MISONIX REPORTS FOURTH QUARTER AND FISCAL YEAR 2021 FINANCIAL RESULTS

Exhibit 99.1 Draft V5 For Immediate Release News Announcement MISONIX REPORTS FOURTH QUARTER AND FISCAL YEAR 2021 FINANCIAL RESULTS FARMINGDALE, N.Y., September 2, 2021 ? Misonix, Inc. (Nasdaq: MSON) (?Misonix? or the ?Company?), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today reported unaudited financial resul

Notice of Nonrenewal and Letter Agreement, dated August 2, 2021

Exhibit 10.1

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 12, 2021 (July 26, 2021) MISONIX, INC. (Exact name of Registrant as specified in its charter) Delaware 001-10986 84-1856018 (State or Other Jurisdiction of Incorporation) (Comm

Bioventus LLC (Update) July 29, 2021

Filed by Misonix, Inc. Pursuant to Rule 425 Under the Securities Act of 1933 And Deemed Filed Pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Misonix, Inc. Commission File No. 001-10986 Bioventus LLC (Update) July 29, 2021 Corporate Speakers: ? Thomas Hill; Bioventus LLC; Director, Corporate Communications ? Ken Reali; Bioventus Inc.; CEO & Director ? Stavros Viz

Bioventus LLC (Update) July 29, 2021

Filed by Bioventus Inc. Pursuant to Rule 425 Under the Securities Act of 1933 And Deemed Filed Pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Misonix, Inc. Commission File No. 001-10986 This filing relates to the proposed acquisition of Misonix, Inc., a Delaware corporation (?Misonix?) by Bioventus Inc., a Delaware corporation (?Bioventus?), pursuant to the term

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2021 MISONIX, INC. (Exact name of registrant as specified in its charter) Delaware 001-10986 84-1856018 (State or other jurisdiction of incorporation) (Commission File Number

Agreement and Plan of Merger, dated as of July 29, 2021, by and among Misonix, Bioventus, First Merger Sub and Second Merger Sub*

Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among: BIOVENTUS INC., a Delaware corporation; OYSTER MERGER SUB I, INC., a Delaware corporation; OYSTER MERGER SUB II, LLC, a Delaware limited liability company; and MISONIX, INC. a Delaware corporation Dated as of July 29, 2021 TABLE OF CONTENTS Page ARTICLE I. THE MERGERS 2 Section 1.1 The Mergers; Effect of Mergers 2 Section 1.2 Closing; Effectiv

Bioventus and Misonix Announce Definitive Agreement for Bioventus Acquire Misonix The Combination Further Differentiates Bioventus’ Product Portfolio and Accelerates Its Revenue Growth

Exhibit 99.3 Bioventus and Misonix Announce Definitive Agreement for Bioventus to Acquire Misonix The Combination Further Differentiates Bioventus? Product Portfolio and Accelerates Its Revenue Growth ? Significantly Expands TAM and Adds Considerable Scale and Scope in Spine and Lower Extremity ? Enhances Surgical Solutions Vertical by Adding Minimally Invasive Ultrasonic Technologies That Improve

Filed by Bioventus Inc.

Filed by Bioventus Inc. Pursuant to Rule 425 Under the Securities Act of 1933 And Deemed Filed Pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Misonix, Inc. Commission File No. 001-10986 This filing relates to the proposed acquisition of Misonix, Inc., a Delaware corporation (?Misonix?) by Bioventus Inc., a Delaware corporation (?Bioventus?), pursuant to the term

MISONIX REPORTS PRELIMINARY FISCAL 2021 FOURTH QUARTER AND FULL YEAR REVENUE RESULTS Company Enters into a Definitive Merger Agreement to be Acquired by Bioventus for $518 Million in a Cash-and-Stock Transaction

Exhibit 99.2 MISONIX REPORTS PRELIMINARY FISCAL 2021 FOURTH QUARTER AND FULL YEAR REVENUE RESULTS Company Enters into a Definitive Merger Agreement to be Acquired by Bioventus for $518 Million in a Cash-and-Stock Transaction FARMINGDALE, N.Y., July 29, 2021 ? ? Misonix, Inc. (Nasdaq: MSON) (?Misonix? or the ?Company?), a provider of minimally invasive therapeutic ultrasonic medical devices and reg

Bioventus and Misonix Announce Definitive Agreement for Bioventus to Acquire Misonix The Combination Further Differentiates Bioventus’ Product Portfolio and Accelerates Its Revenue Growth

Filed by Bioventus Inc. Pursuant to Rule 425 Under the Securities Act of 1933 And Deemed Filed Pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Misonix, Inc. Commission File No. 001-10986 This filing relates to the proposed acquisition of Misonix, Inc., a Delaware corporation (?Misonix?) by Bioventus Inc., a Delaware corporation (?Bioventus?), pursuant to the term

Bioventus Voting and Support Agreement, dated as of July 29, 2021, by and among Misonix and the Bioventus Supporting Stockholders

Exhibit 10.1 Execution Version VOTING AND SUPPORT AGREEMENT This VOTING AND SUPPORT AGREEMENT (this ?Agreement?) is entered into as of July 29, 2021, by and between Misonix, Inc., a Delaware corporation (the ?Company?), and the persons set forth on Schedule A attached hereto (each, a ?Stockholder? and, collectively, the ?Stockholders?). Capitalized terms used but not otherwise defined herein shall

FORM OF VOTING AND SUPPORT AGREEMENT

Exhibit 99.1 Execution Version FORM OF VOTING AND SUPPORT AGREEMENT This VOTING AND SUPPORT AGREEMENT (this ?Agreement?) is entered into as of July [ ], 2021, by and between Bioventus Inc., a Delaware corporation (?Parent?), and the persons set forth on Schedule A attached hereto (each, a ?Stockholder? and, collectively, the ?Stockholders?). Capitalized terms used but not otherwise defined herein

Question: How did Misonix emerge as an acquisition target?

Exhibit 99.5 Question: How did Misonix emerge as an acquisition target? ? Answer: We began looking at Misonix as a means to scale our BGS business via a differentiated, non-hardware technology. ? We began looking as part of our routine and extensive review of M&A opportunities. ? Once we had the opportunity to interact directly with Misonix, it not only validated our initial thesis, but identified

Transaction Details Transaction Terms In the transaction, Misonix stockholders may elect to receive either (i) 1.6839 shares of Bioventus class A common stock or (ii) $28.00 in cash, without interest, for each share of Misonix common stock they hold,

Bioventus? Acquisition of Misonix July 29, 2021 Exhibit 99.4 Transaction Details Transaction Terms In the transaction, Misonix stockholders may elect to receive either (i) 1.6839 shares of Bioventus class A common stock or (ii) $28.00 in cash, without interest, for each share of Misonix common stock they hold, subject to proration based on an aggregate maximum cash amount payable by Bioventus equa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2021 MISONIX, INC. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2021 MISONIX, INC. (Exact name of registrant as specified in its charter) Delaware 001-10986 84-1856018 (State or other jurisdiction of incorporation) (Commission File Number

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2021 Bioventus Inc. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2021 Bioventus Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37844 81-0980861 (Commission File Numbe

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 23, 2021 MISONIX, INC. (Exact name of Registrant as specified in its charter) Delaware 001-10986 84-1856018 (State or Other Jurisdiction of Incorporation) (Commission File Number

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 14, 2021 (May 12, 2021) MISONIX, INC. (Exact name of Registrant as specified in its charter) Delaware 001-10986 84-1856018 (State or Other Jurisdiction of Incorporation) (Commissi

10.10 Misonix, Inc. Employee Stock Purchase Plan (15)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

Misonix Appoints Patrick J. Beyer to Board of Directors Leading Medical Tech Executive Brings Extensive Industry Knowledge, Strategic Leadership and Financial Expertise to Board

Exhibit 99.1 For Immediate Release News Announcement Misonix Appoints Patrick J. Beyer to Board of Directors Leading Medical Tech Executive Brings Extensive Industry Knowledge, Strategic Leadership and Financial Expertise to Board FARMINGDALE, N.Y., May 14, 2021 ? Misonix, Inc. (Nasdaq: MSON) (?Misonix? or the ?Company?), a provider of minimally invasive therapeutic ultrasonic medical devices and

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 6, 2021 MISONIX, INC. (Exact name of Registrant as specified in its charter) Delaware 001-10986 84-1856018 (State or Other Jurisdiction (Commission (IRS Employer of Incorporation)

Quarterly Report -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to .

MISONIX REPORTS FISCAL 2021 THIRD QUARTER FINANCIAL RESULTS Misonix Raises Guidance for neXus® Ultrasonic Surgical System to 200 Unit Placements by Fiscal 2021 Year-End

Exhibit 99.1 For Immediate Release News Announcement MISONIX REPORTS FISCAL 2021 THIRD QUARTER FINANCIAL RESULTS Misonix Raises Guidance for neXus? Ultrasonic Surgical System to 200 Unit Placements by Fiscal 2021 Year-End FARMINGDALE, N.Y., May 6, 2021 ? Misonix, Inc. (Nasdaq: MSON) (?Misonix? or the ?Company?), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerati

Misonix, Inc. 1938 New Highway Farmingdale, NY 11735 April 30, 2021

Misonix, Inc. 1938 New Highway Farmingdale, NY 11735 April 30, 2021 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attn: Ada D. Sarmento Re: Misonix, Inc. Registration Statement on Form S-3 (Registration No. 333-255442) Ladies and Gentlemen: On behalf of Misonix, Inc. (the ?Company?), the undersign

-

S-3 1 forms-3.htm As filed with the Securities and Exchange Commission on April 22, 2021. Registration No. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT Under The Securities Act of 1933 MISONIX, INC. (Exact name of Registrant as specified in its charter) Delaware 84-1856018 (State or other jurisdiction of (I.R.S. Employer incorporation or o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Misonix, Inc. (Name of Issuer) Common Shares, $0.0001 par value (Title of Class of Securities) (CUSIP

SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Misonix, Inc. (Name of Issuer) Common Shares, $0.0001 par value (Title of Class of Securities) 604871103 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule p

JOINT FILING AGREEMENT

EX-99.A EXHIBIT A JOINT FILING AGREEMENT In accordance with Rule 16a-3(j) and Rule 13d-1(k)(1) and under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of Forms 3, 4, 5 and Schedules 13D and 13G (including any and all amendments thereto) with respect to the Common Shares, $0.0001 par value, of Misonix, Inc. and further agree tha

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Misonix, Inc. (Name of Issuer) Common Shares, $0.0001 par value (Title of Class of Securities) (CUSIP Nu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Misonix, Inc. (Name of Issuer) Common Shares, $0.0001 par value (Title of Class of Securities) 604871103 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to

MISONIX REPORTS FISCAL 2021 SECOND QUARTER FINANCIAL RESULTS

Exhibit 99.1 MISONIX REPORTS FISCAL 2021 SECOND QUARTER FINANCIAL RESULTS FARMINGDALE, N.Y., February 4, 2021 — Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today reported financial results for the fiscal 2021 second quarter ended December 31, 2020 as summ

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 4, 2021 MISONIX, INC. (Exact name of Registrant as specified in its charter) Delaware 001-10986 84-1856018 (State or Other Jurisdiction (Commission (IRS Employer of Incorpora

Quarterly Report -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to .

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 4, 2021 (February 2, 2021) MISONIX, INC. (Exact name of Registrant as specified in its charter) Delaware 001-10986 84-1856018 (State or Other Jurisdiction of Incorporation) (

Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 17, 2020 (December 16, 2020) MISONIX, INC. (Exact name of Registrant as specified in its charter) Delaware 001-10986 84-1856018 (State or Other Jurisdiction of Incorporation)

Third Amendment to Amended and Restated Credit Agreement dated as of December 16, 2020 by and Among Solsys Medical, LLC and Misonix, Inc. as borrowers, each of the financial institutions signatories thereto and SWK Funding LLC, as administrative agent

Exhibit 10.1 THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT THIS THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT (this “Amendment”), dated as of December 16, 2020, is entered into by and among SOLSYS MEDICAL, LLC, a Delaware limited liability company formerly known as Soluble Systems, LLC (“Soluble”), MISONIX, INC., a Delaware corporation formerly known as New Misonix, Inc. (“Mi

Quarterly Report -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to .

Results of Operations and Financial Condition, Financial Statements and Exhibits -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 5, 2020 MISONIX, INC. (Exact name of Registrant as specified in its charter) Delaware 001-10986 84-1856018 (State or Other Jurisdiction of Incorporation) (Commission File Num

MISONIX FISCAL 2021 FIRST QUARTER REVENUE RISES 59% TO $17.7 MILLION

Exhibit 99.1 For Immediate Release MISONIX FISCAL 2021 FIRST QUARTER REVENUE RISES 59% TO $17.7 MILLION FARMINGDALE, N.Y., November 5, 2020 — Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today reported unaudited financial results for the fiscal 2021 first

Results of Operations and Financial Condition, Financial Statements and Exhibits -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 6, 2020 MISONIX, INC. (Exact name of Registrant as specified in its charter) Delaware 001-10986 84-1856018 (State or Other Jurisdiction of Incorporation) (Commission File Numb

Confirms Improving Revenue Trends, Rise in Procedure Volumes and Strong New Product Adoption

Exhibit 99.1 MISONIX REPORTS PRELIMINARY FISCAL 2021 FIRST QUARTER REVENUE OF APPROXIMATELY $17.7 MILLION Confirms Improving Revenue Trends, Rise in Procedure Volumes and Strong New Product Adoption FARMINGDALE, N.Y., (October 6, 2020) – Misonix, Inc. (Nasdaq: MSON) (“Misonix,” the “Company,” “we,” “us” or “our”), a provider of minimally invasive therapeutic ultrasonic medical devices and regenera

Annual Report -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-10986 MISONIX, INC.

MISONIX REPORTS FOURTH QUARTER AND FISCAL YEAR 2020 RESULTS

Exhibit 99.1 MISONIX REPORTS FOURTH QUARTER AND FISCAL YEAR 2020 RESULTS FARMINGDALE, N.Y., September 3, 2020 — Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today reported unaudited financial results for the fiscal 2020 fourth quarter and full fiscal year

Results of Operations and Financial Condition, Financial Statements and Exhibits -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 3, 2020 MISONIX, INC. (Exact name of Registrant as specified in its charter) New York 001-10986 84-1856018 (State or Other Jurisdiction (Commission (IRS Employer of Incorpor

-

As filed with the Securities and Exchange Commission on September 3, 2020 Registration No.

10.28 First Loan Modification Agreement dated January 6, 2020 between Misonix, Inc., Solsys Medical, LLC, Misonix OpCo, Inc. and Silicon Valley Bank (33)

Exhibit 10.30 First LOAN MODIFICATION AGREEMENT This First Loan Modification Agreement (this “Loan Modification Agreement”) is entered into as of January 3, 2020, by and among (a) SILICON VALLEY BANK, a California corporation, with its principal place of business at 3003 Tasman Drive, Santa Clara, California 95054 (“Bank”) and (b) (i) MISONIX, INC., a Delaware corporation (“Parent”), (ii) MISONIX

2017 Equity Incentive Plan, as amended

Exhibit 10.19 MISONIX, INC. 2017 EQUITY INCENTIVE PLAN, AS AMENDED Section 1. Purpose. The purposes of this Misonix, Inc. 2017 Equity Incentive Plan (the “Plan”) are (1) to make available to key employees, directors and consultants certain compensatory arrangements related to the growth in value of the common stock of the Company so as to generate an increased incentive to contribute to the Compan

Description of securities registered under Section 12 of the Exchange Act

Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Misonix, Inc., a Delaware corporation, has one class of equity securities registered under Section 12 of the Securities Exchange Act of 1934: common stock, par value $0.0001 per share (“common stock”). Our preferred stock, par value $0.0001 per share (“preferred stock”),

Subsidiaries of the Registrant

Exhibit 21.1 Subsidiaries of Misonix, Inc. Name of Subsidiary Jurisdiction of Incorporation Misonix OpCo, Inc. New York Solsys Medical, LLC Delaware

Restated Certificate of Incorporation of the Company.

Exhibit 3 (a) CERTIFICATE OF INCORPORATION OF MISONIX, INC., A STOCK CORPORATION I, the undersigned, for the purpose of incorporating and organizing a corporation under the General Corporation Law of the State of Delaware, do hereby certify as follows: ARTICLE I The name of the corporation is Misonix, Inc. (the “Corporation”). ARTICLE II The address of the Corporation’s registered office in the St

Results of Operations and Financial Condition, Financial Statements and Exhibits

8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 10, 2020 MISONIX, INC. (Exact name of Registrant as specified in its charter) New York 001-10986 11-2148932 (State or Other Jurisdiction of Incorporation) (Comm

MISONIX REPORTS PRELIMINARY FISCAL 2020 FOURTH QUARTER REVENUE OF APPROXIMATELY $13.5 MILLION FULL YEAR REVENUE OF APPROXIMATELY $62.3 MILLION Company Focus on Shareholder Value Creation, Cash Preservation, Expense Reduction, Workforce Efficiency and

Exhibit 99.1 MISONIX REPORTS PRELIMINARY FISCAL 2020 FOURTH QUARTER REVENUE OF APPROXIMATELY $13.5 MILLION FULL YEAR REVENUE OF APPROXIMATELY $62.3 MILLION Company Focus on Shareholder Value Creation, Cash Preservation, Expense Reduction, Workforce Efficiency and Operational Synergies FARMINGDALE, N.Y., (July 10, 2020) – Misonix, Inc. (Nasdaq: MSON) (“Misonix,” the “Company,” “we,” “us” or “our”),

10.29 Second Loan Modification Agreement dated June 30, 2020 between Misonix, Inc., Solsys Medical, LLC, Misonix OpCo, Inc. and Silicon Valley Bank (34)

Exhibit 10.2 Certain information has been excluded from the exhibit because it is not material and would likely cause competitive harm to the company if publicly disclosed. [***] indicates the redacted confidential portions of this exhibit. SECOND LOAN MODIFICATION AGREEMENT This Second Loan Modification Agreement (this “Loan Modification Agreement”) is entered into as of June 30, 2020, by and amo

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 1, 2020 (June 30, 2020) MISONIX, INC. (Exact name of Registrant as specified in its charter) New York 001-10986 84- 1856018 (State or Other Jurisdiction of Incorporation) (Commis

Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 1, 2020 (June 30, 2020) MISONIX, INC. (Exact name of Registrant as specified in its charter) New York 001-10986 84- 1856018 (State or Other Jurisdiction of Incorporation) (Commis

10.26 Second Amendment to Amended and Restated Credit Agreement dated June 30, 2020 between Solsys Medical, LLC and Misonix, Inc. as borrowers, each of the financial institutions signatories thereto and SWK Funding LLC, as administrative agent (31)

Exhibit 10.1 Certain information has been excluded from the exhibit because it is not material and would likely cause competitive harm to the company if publicly disclosed. [***] indicates the redacted confidential portions of this exhibit. SECOND AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT THIS SECOND AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT (this “Amendment”), dated as of June 3

- DEFINITIVE REVISED PROXY STATEMENT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi

10.18 2017 Equity Incentive Plan, as amended (23)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant S Filed by a Party other than the Registrant £ Check the appropriate box: £ Preliminary Proxy Statement £ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) S Defin

Quarterly Report - QUARTERLY REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to .

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 11, 2020 MISONIX, INC. (Exact name of Registrant as specified in its charter) New York 001-10986 11-2148932 (State or Other Jurisdiction (Commission File Number) (IRS Employer of

MISONIX FISCAL 2020 THIRD QUARTER REVENUE RISES TO $17.9 MILLION

Exhibit 99.1 MISONIX FISCAL 2020 THIRD QUARTER REVENUE RISES TO $17.9 MILLION FARMINGDALE, N.Y., May 11, 2020 - Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today reported financial results for the fiscal 2020 third quarter ended March 31, 2020 as summariz

Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 10, 2020 MISONIX, INC. (Exact name of Registrant as specified in its charter) New York 001-10986 84- 1856018 (State or Other Jurisdiction of Incorporation) (Commission File Numb

10.30 Promissory Note dated April 5, 2020 between Misonix, Inc. and J.P. Morgan Chase Bank, N.A. (35)

Exhibit 10.1

MISONIX REPORTS PRELIMINARY FISCAL 2020 THIRD QUARTER REVENUE OF APPROXIMATELY $17.9 MILLION With Focus on Maintaining Our Objective of Shareholder Value Creation, Company to Prioritize Cash Preservation Through Expense Reduction, Workforce Efficienc

Exhibit 99.1 For Immediate Release MISONIX REPORTS PRELIMINARY FISCAL 2020 THIRD QUARTER REVENUE OF APPROXIMATELY $17.9 MILLION With Focus on Maintaining Our Objective of Shareholder Value Creation, Company to Prioritize Cash Preservation Through Expense Reduction, Workforce Efficiency and Operational Synergies FARMINGDALE, N.Y., April 2, 2020 - Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Comp

Financial Statements and Exhibits, Results of Operations and Financial Condition, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 2, 2020 MISONIX, INC. (Exact name of Registrant as specified in its charter) New York 001-10986 11-2148932 (State or Other Jurisdiction of Incorporation) (Commission File Number

MSON / Misonix, Inc. / Svlsf Vi, Llc - SC 13G/A Passive Investment

SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Misonix, Inc. (Name of Issuer) Common Shares, $0.0001 par value (Title of Class of Securities) 604871103 (CUSIP Number) December 31, 2019 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule p

10.23 Amendment to the Second Amended and Restated Distribution and Supply Agreement dated January 20, 2020 by and among Skin and Wound Allograft Institute, LLC and Solsys Medical, LLC. (28)

Exhibit 10.2 Amendment to Second Amended and Restated Distribution and Supply Agreement This Amendment to the Second Amended and Restated Distribution and Supply Agreement (the “Amendment”) is made effective upon signature by and among Skin and Wound Allograft Institute, LLC, a Virginia limited liability company and wholly-owned subsidiary of LifeNet Health, with its principal place of business at

MISONIX REPORTS RECORD QUARTERLY REVENUE OF $19.7 MILLION FOR FISCAL 2020 SECOND QUARTER

Exhibit 99.1 MISONIX REPORTS RECORD QUARTERLY REVENUE OF $19.7 MILLION FOR FISCAL 2020 SECOND QUARTER FARMINGDALE, N.Y., February 5, 2020 - Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today reported financial results for the fiscal 2020 second quarter end

10.22 Second Amended and Restated Distribution and Supply Agreement dated October 17, 2017 by and between Skin and Wound Allograft Institute, LLC and Soluble Systems, LLC. (27)

Exhibit 10.1 Certain information has been excluded from the exhibit because it is not material and would likely cause competitive harm to the company if publicly disclosed. [***] indicates the redacted confidential portions of this exhibit. SECOND AMENDED AND RESTATED DISTRIBUTION AND SUPPLY AGREEMENT October 13, 2017 This Second Amended and Restated Distribution and Supply Agreement (the “Agreeme

MSON / Misonix, Inc. 10-Q - Quarterly Report - QUARTERLY REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to .

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 5, 2020 MISONIX, INC. (Exact name of Registrant as specified in its charter) New York 001-10986 11-2148932 (State or Other Jurisdiction of Incorporation) (Commission File Num

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 27, 2020 (January 23, 2020) MISONIX, INC. (Exact name of Registrant as specified in its charter) Delaware 001-10986 84-1856018 (State or Other Jurisdiction of Incorporation) (

Underwriting Agreement, dated January 23, 2020, by and among the Company and Canaccord Genuity LLC, acting as representative of the several underwriters named therein.

Exhibit 1.1 Misonix, Inc. (a Delaware corporation) 1,625,000 Shares of Common Stock UNDERWRITING AGREEMENT January 23, 2020 Canaccord Genuity LLC as Representative of the several Underwriters c/o Canaccord Genuity LLC 99 High Street, 12th Floor, Boston, MA 02110 Ladies and Gentlemen: Misonix, Inc., a Delaware corporation (the “Company”), confirms its agreement with Canaccord Genuity LLC (“Canaccor

1,625,000 Shares Common Stock

Filed Pursuant to Rule 424(b)(2) Registration No. 333-223878 PROSPECTUS SUPPLEMENT (To Prospectus dated November 25, 2019) 1,625,000 Shares Common Stock We are offering 1,625,000 shares of our common stock pursuant to this prospectus supplement and the accompanying prospectus. Our common stock is listed on The Nasdaq Global Market under the symbol “MSON.” On January 21, 2020, the closing price of

Financial statements of Solsys Medical, LLC

Exhibit 99.2 INDEPENDENT AUDITOR’S REPORT To the Board of Directors Solsys Medical, LLC Newport News, Virginia Report on the Financial Statements We have audited the accompanying financial statements of Solsys Medical, LLC (the Company), which comprise the balance sheets as of December 31, 2018 and 2017, the related statements of operations, changes in members’ deficit and cash flows for the years

Updated Risk Factor Disclosure

Exhibit 99.1 As used in this Exhibit 99.1, we refer to Misonix, Inc. and its subsidiaries (unless the context otherwise requires) as “we,” “us,” “our,” the “Company” or “Misonix.” USE OF FORWARD-LOOKING STATEMENTS This Exhibit 99.1 contain statements that we believe are “forward-looking statements” as that term is used in the Private Securities Litigation Reform Act of 1995 and are intended to enj

SUBJECT TO COMPLETION, DATED JANUARY 22, 2020

Filed Pursuant to Rule 424(b)(5) Registration No. 333-223878 The information in this preliminary prospectus is not complete and may be changed. The securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell nor does it seek an offer to buy these securities in any jurisdiction where

MSON / Misonix, Inc. 8-K12B/A - - AMENDMENT NO. 2 TO FORM 8-K12B

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 2) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 22, 2020 (September 27, 2019) MISONIX, INC. (Exact name of Registrant as specified in its charter) Delaware 001-10986 84- 1856018 (State or Other Jurisdict

Results of Operations and Financial Condition, Financial Statements and Exhibits

8-K 1 f8k011320misonixinc.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 16, 2020 (January 13, 2020) MISONIX, INC. (Exact name of Registrant as specified in its charter) Delaware 001-10986 84- 1856018 (S

MISONIX REPORTS PRELIMINARY FISCAL 2020 SECOND QUARTER REVENUE OF APPROXIMATELY $19.7 MILLION Reiterates Expectation for Fiscal 2020 Full Year Pro Forma Revenue Growth of 20%

Exhibit 99.1 MISONIX REPORTS PRELIMINARY FISCAL 2020 SECOND QUARTER REVENUE OF APPROXIMATELY $19.7 MILLION Reiterates Expectation for Fiscal 2020 Full Year Pro Forma Revenue Growth of 20% FARMINGDALE, N.Y., January 13, 2020 - Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clin

MSON / Misonix, Inc. / South Africa Alpha Capital Management Ltd. Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Misonix, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 604871103 (CUSIP Number) December 31, 2019 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu

10.27 Loan and Security Agreement dated December 26, 2019 between Misonix, Inc., Solsys Medical, LLC, Misonix OpCo, Inc. and Silicon Valley Bank (32)

Exhibit 10.2 Certain information has been excluded from the exhibit because it is not material and would likely cause competitive harm to the company if publicly disclosed. [***] indicates the redacted confidential portions of this exhibit. LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (this “Agreement”) dated as of December 26, 2019 (the “Effective Date”) by and among (a) SILICON V

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Entry into a Material Definitive Agreement, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 30, 2019 (December 23, 2019) MISONIX, INC. (Exact name of Registrant as specified in its charter) New York 001-10986 84- 1856018 (State or Other Jurisdiction of Incorporation

10.25 First Amendment to Amended and Restated Credit Agreement dated December 23, 2019 between Solsys Medical, LLC and Misonix, Inc. as borrowers, each of the financial institutions signatories thereto and SWK Funding LLC, as administrative agent (2930)

Exhibit 10.1 Certain information has been excluded from the exhibit because it is not material and would likely cause competitive harm to the company if publicly disclosed. [***] indicates the redacted confidential portions of this exhibit. FIRST AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT THIS FIRST AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT (this “Amendment”), dated as of December

Letter from BDO USA, LLP dated December 4, 2019

Exhibit 16.1 December 4, 2019 Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 We have been furnished with a copy of the response to Item 4.01 of Form 8-K for the event that occurred on December 3, 2019, to be filed by our former client, Misonix, Inc. We agree with the statements made in response to that Item insofar as they relate to our Firm. Very truly yours, /s/ BDO

Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 4, 2019 (December 3, 2019) MISONIX, INC. (Exact name of Registrant as specified in its charter) New York 001-10986 84-1856018 (State or Other Jurisdiction of Incorporation) (

Unaudited pro forma condensed consolidated combined statements of operations for the year ended June 30, 2019 and for the three months ended September 30, 2019

Exhibit 99.2 UNAUDITED PRO FORMA CONDENSED CONSOLIDATED COMBINED FINANCIAL INFORMATION The following unaudited pro forma condensed consolidated combined financial statements are derived from the separate historical financial statements of Misonix, Inc. (“Misonix”) and Solsys Medical, LLC (“Solsys”) after giving effect to the acquisition of Solsys by Misonix (the “Transaction”), and are based on th

Balance sheet as of June 30, 2019 of Solsys and the related statements of operations, changes in members’ deficit and cash flows for the six month periods ended June 30, 2019 and 2018, together with the related notes thereto and the independent accountant’s review report thereon

Exhibit 99.1 SOLSYS MEDICAL, LLC (A Delaware Limited Liability Company) FInancial Report June 30, 2019 and 2018 CONTENTS INDEPENDENT ACCOUNTANT’S REVIEW REPORT 1 - 2 FINANCIAL STATEMENTS Balance sheets 3 - 4 Statements of operations 5 Statements of changes in members’ deficit 6 Statements of cash flows 7 Notes to financial statements 8 - 18 -i- INDEPENDENT ACCOUNTANT’S REVIEW REPORT To the Board o

MSON / Misonix, Inc. POS AM - - POST-EFFECTIVE AMENDMENT NO. 2 TO FORM S-3

As filed with the Securities and Exchange Commission on November 22, 2019 Registration No.

November 22, 2019

8-K12B/A 1 f8k12b092719a1misonixinc.htm AMENDMENT NO. 1 TO FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 22, 2019 (September 27, 2019) MISONIX, INC. (Exact name of Registrant as specified in

Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to .

MISONIX FISCAL 2020 FIRST QUARTER RECORD QUARTERLY PRODUCT REVENUE OF $11.1 MILLION

Exhibit 99.1 MISONIX FISCAL 2020 FIRST QUARTER RECORD QUARTERLY PRODUCT REVENUE OF $11.1 MILLION FARMINGDALE, N.Y., (November 7, 2019) – Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today reported financial results for the fiscal 2020 first quarter ended S

Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K 1 f8k110719misonixinc.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 7, 2019 MISONIX, INC. (Exact name of Registrant as specified in its charter) New York 001-10986 11-2148932 (State or Other Jurisd

MSON / Misonix, Inc. 15-12B - - NOTICE OF TERMINATION OF REGISTRATION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-10986 MISONIX OPCO, INC. (Exact name of registrant as specified in its c

MSON / Misonix, Inc. / Svlsf Vi, Llc - SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Misonix, Inc. (Name of Issuer) Common Shares, $0.0001 par value (Title of Class of Securities) 604871103 (CUSIP Number) September 27, 2019 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to

MSON / Misonix, Inc. / 1315 Capital, L.p. - SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Misonix, Inc. (Name of Issuer) Common Shares, $0.0001 par value (Title of Class of Securities) 604871103 (CUSIP Number) September 27, 2019 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 1, 2019 MISONIX, INC. (Exact name of Registrant as specified in its charter) Delaware 1-10986 84-1856018 (State or Other Jurisdiction of Incorporation) (Commission File Number

MSON / Misonix, Inc. S-8 POS - - POST-EFFECTIVE AMENDMENT TO FORM S-8

As filed with the Securities and Exchange Commission on October 3, 2019 Registration Nos.

MSON / Misonix, Inc. S-8 POS - - POST-EFFECTIVE AMENDMENT TO FORM S-8

As filed with the Securities and Exchange Commission on October 3, 2019 Registration Nos.

MSON / Misonix, Inc. S-8 POS - - POST-EFFECTIVE AMENDMENT TO FORM S-8

As filed with the Securities and Exchange Commission on October 3, 2019 Registration Nos.

MSON / Misonix, Inc. S-8 POS - - POST-EFFECTIVE AMENDMENT TO FORM S-8

As filed with the Securities and Exchange Commission on October 3, 2019 Registration Nos.

MSON / Misonix, Inc. S-8 POS - - POST-EFFECTIVE AMENDMENT TO FORM S-8

S-8 POS 1 fs8pos2019misonix.htm POST-EFFECTIVE AMENDMENT TO FORM S-8 As filed with the Securities and Exchange Commission on October 3, 2019 Registration Nos. 333-219348 333-203944 333-188554 333-165088 333-130874 333-63166 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 (NO. 333-219348) POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 (

MSON / Misonix, Inc. S-8 POS - - POST-EFFECTIVE AMENDMENT TO FORM S-8

As filed with the Securities and Exchange Commission on October 3, 2019 Registration Nos.

Amended and Restated Bylaws of Misonix OpCo, Inc.

Exhibit 3.5 AMENDED AND RESTATED BY-LAWS OF MISONIX OPCO, INC. ARTICLE I OFFICES Section 1. Principal Office. The principal office of Misonix OpCo, Inc. (the “Corporation”) shall be located in the County of Suffolk, New York. Section 2. Other Offices. The Corporation may have such other offices and places of business, within or without the State of New York, as the board of directors of the Corpor

10.1 Form of Indemnification Agreement (6)

Exhibit 10.2 form of INDEMNIFICATION AGREEMENT This Indemnification Agreement (this “Agreement”), dated as of , 2019, is made by and between New Misonix, Inc., a Delaware corporation (the “Company”), and (“Indemnitee”). RECITALS WHEREAS, the Board has determined that the Company should act to assure directors and officers of the Company that there shall be adequate certainty of protection through

Certificate of Amendment to the Certificate of Incorporation of New Misonix, Inc. (incorporated by reference to Exhibit 3.3 to the Registrant’s Current Report on Form 8-K filed September 27, 2019)

Exhibit 3.3 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF NEW MISONIX, INC. New Misonix, Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware (the “DGCL”), hereby certifies as follows: 1. This Certificate of Amendment amends the provisions of the Corporation’s Certificate of Incorporation of the Corporation file

September 27, 2019

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 27, 2019 MISONIX, INC. (Exact name of Registrant as specified in its charter) Delaware 1-10986 84-1856018 (State or Other Jurisdiction of Incorporation) (Commission File Num

Press Release, dated September 27, 2019

Exhibit 99.1 MISONIX, INC. COMPLETES ACQUISITION OF REGENERATIVE MEDICAL COMPANY SOLSYS MEDICAL FARMINGDALE, N.Y., (September 27, 2019) – Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical outcomes, announced today that it completed its previously announced acquisition of privately held Solsys Med

Amended and Restated Certificate of Incorporation of Misonix OpCo, Inc.

Exhibit 3.4 CERTIFICATE OF INCORPORATION OF MISONIX OPCO, INC. Under Section 402 of The Business Corporation Law FIRST: The name of the corporation is Misonix OpCo, Inc. (the “Corporation”). SECOND: The office of Corporation is to be located in the County of Suffolk, State of New York. THIRD: The purpose of the Corporation is to engage in any lawful act or activity for which corporations may be or

10.24 Amended and Restated Credit Agreement dated September 27, 2019 between Solsys Medical, LLC and New Misonix, Inc. as borrowers, each of the financial institutions signatories thereto and SWK Funding LLC, as administrative agent (29)

Exhibit 10.1 AMENDED AND RESTATED CREDIT AGREEMENT among SOLSYS MEDICAL, LLC, and NEW MISONIX, INC., as Borrower, SWK FUNDING LLC, as Agent, Sole Lead Arranger and Sole Bookrunner, and the financial institutions party hereto from time to time as Lenders Dated as of September 27, 2019 [Solsys Medical] A&R Credit Agreement Table of Contents Page Section 1 Definitions; Interpretation 1 1.1 Definition

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 26, 2019 MISONIX, INC. (Exact name of Registrant as specified in its charter) New York 001-10986 11-2148932 (State or Other Jurisdiction of Incorporation) (Commission File N

MSON / Misonix, Inc. DEFA14A - - DEFINITIVE ADDITIONAL MATERIALS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

Form 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-10986 MISONIX, INC.

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 15, 2019 MISONIX, INC. (Exact name of Registrant as specified in its charter) New York 001-10986 11-2148932 (State or Other Jurisdiction of Incorporation) (Commission File Numb

MSON / Misonix, Inc. 425 - Merger Prospectus - FORM 425

Filed by Misonix, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Solsys Medical, LLC and Misonix, Inc. Commission File No.: 333-231797 August 15, 2019 C O R P O R A T E P A R T I C I P A N T S Norberto Aja, Investor Relations, JCIR Stavros Vizirgianakis, President and Chief Executive Off

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August [14], 2019 MISONIX, INC. (Exact name of Registrant as specified in its charter) New York 001-10986 11-2148932 (State or Other Jurisdiction of Incorporation) (Commission File Nu

MISONIX REPORTS FOURTH QUARTER AND FISCAL YEAR 2019 RESULTS

Exhibit 99.1 MISONIX REPORTS FOURTH QUARTER AND FISCAL YEAR 2019 RESULTS FARMINGDALE, N.Y., (August 14, 2019) – Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical outcomes, today reported financial results for the fiscal 2019 fourth quarter and year ended June 30, 2019 as summarized below: Three M

MSON / Misonix, Inc. 425 - Merger Prospectus - 425

425 Filed by Misonix, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Solsys Medical, LLC and Misonix, Inc. Commission File No.: 333-231797 August 13, 2019 Canaccord Annual Growth Conference August 8, 2019 Misonix UpdateCanaccord Annual Growth Conference August 8, 2019 Misonix Update Forw

MSON / Misonix, Inc. CORRESP - -

CORRESP July 5, 2019 Mr. Tim Buchmiller Mr. Russel Mancuso Division of Corporation Finance Office of Electronics and Machinery United States Securities and Exchange Commission Washington, DC 20549 Re: Misonix, Inc. Form 10-K for the Fiscal Year Ended June 30, 2018 Form 10-Q for the Quarterly Period Ended March 31, 2019 File No. 001-10986 Dear Messrs. Buchmiller and Mancuso: Set forth below are the

Financial Statements and Exhibits, Other Events

8-K 1 f8k061819misonixinc.htm CURREMT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 18, 2019 MISONIX, INC. (Exact name of Registrant as specified in its charter) New York 001-10986 11-2148932 (State or Other Jurisdict

SEC INVESTIGATION OF MISONIX, INC. ENDS WITH NO ACTION

Exhibit 99.1 News Announcement For Immediate Release SEC INVESTIGATION OF MISONIX, INC. ENDS WITH NO ACTION FARMINGDALE, N.Y., (June 20, 2019) – Misonix, Inc. (Nasdaq: MSON) (“Misonix”), a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical outcomes, today announced that it has received a letter from the Division of Enforcement of the Securities and Exchange

Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 3, 2019 MISONIX, INC. (Exact name of Registrant as specified in its charter) New York 001-10986 11-2148932 (State or Other Jurisdiction of Incorporation) (Commission File Number)

MISONIX RECEIVES U.S. FDA CLEARANCE FOR NEXUS, ITS REVOLUTIONARY INTEGRATED ULTRASONIC SURGICAL PLATFORM

Exhibit 99.1 News Announcement For Immediate Release MISONIX RECEIVES U.S. FDA CLEARANCE FOR NEXUS, ITS REVOLUTIONARY INTEGRATED ULTRASONIC SURGICAL PLATFORM FARMINGDALE, N.Y., (June 3, 2019) – Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical outcomes, today announced that it received 510(k) cle

STIPULATION OF SETTLEMENT

Exhibit 99.2 UNITED STATES DISTRICT COURT EASTERN DISTRICT OF NEW YORK IN RE MISONIX, INC. STOCKHOLDER DERIVATIVE LITIGATION This Document Relates To: ALL DERIVATIVE ACTIONS. Lead Case No. 2:17-cv-03385-ADS-AYS (Consolidated with No. 2:17-cv-03657) Honorable Arthur D. Spatt Courtroom 1020 STIPULATION OF SETTLEMENT This Stipulation of Settlement, dated May 3, 2019 (the “Stipulation”), is made and e

Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 21, 2019 MISONIX, INC. (Exact name of Registrant as specified in its charter) New York 001-10986 11-2148932 (State or Other Jurisdiction of Incorporation) (Commission File Number)

NOTICE OF PROPOSED SETTLEMENT OF DERIVATIVE ACTION, SETTLEMENT HEARING, AND RIGHT TO APPEAR

Exhibit 99.1 UNITED STATES DISTRICT COURT EASTERN DISTRICT OF NEW YORK IN RE MISONIX, INC. STOCKHOLDER DERIVATIVE LITIGATION Lead Case No. 2:17-cv-03385-ADS-AYS (Consolidated with No. 2:17-cv-03657-ADS-GRB) This Document Relates To: ALL DERIVATIVE ACTIONS. Honorable Arthur D. Spatt Courtroom 1020 NOTICE OF PROPOSED SETTLEMENT OF DERIVATIVE ACTION, SETTLEMENT HEARING, AND RIGHT TO APPEAR TO: ALL RE

MSON / Misonix, Inc. 425 Merger Prospectus 425

Filed by Misonix, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Solsys Medical, LLC Commission File No.: 001-10986 May 8, 2019 MISONIX REPORTS FISCAL 2019 THIRD QUARTER REVENUE OF $9.6 MILLION FARMINGDALE, N.Y. (May 8, 2019) – Misonix, Inc. (NASDAQ: MSON) (“Misonix” or the “Company”), a

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 8, 2019 MISONIX, INC. (Exact name of Registrant as specified in its charter) New York 001-10986 11-2148932 (State or Other Jurisdiction of Incorporation) (Commission File Number)

MISONIX REPORTS FISCAL 2019 THIRD QUARTER REVENUE OF $9.6 MILLION

Exhibit 99.1 MISONIX REPORTS FISCAL 2019 THIRD QUARTER REVENUE OF $9.6 MILLION FARMINGDALE, N.Y. (May 8, 2019) – Misonix, Inc. (NASDAQ: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical outcomes, today reported financial results for the fiscal 2019 third quarter ended March 31, 2019 as summarized below: Three Months En

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 8, 2019 (May 7, 2019) MISONIX, INC. (Exact name of Registrant as specified in its charter) New York 001-10986 11-2148932 (State or Other Jurisdiction of Incorporation) (Commission

MSON / Misonix, Inc. 10-Q Quarterly Report 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to .

Articles of Amendment and Restated Certificate of Incorporation of Misonix, Inc.

EXHIBIT 3.1 RESTATED CERTIFICATE OF INCORPORATION OF MISONIX, INC. Under Section 807 of the Business Corporation Law The undersigned, being the President and Secretary of MISONIX, INC., do hereby certify as follows: (1) The name of the Corporation is MISONIX, INC. The name under which the Corporation was formed was HEAT SYSTEMS-ULTRASONICS, INC. (2) The Certificate of Incorporation of the Corporat

Support Agreement, dated May 2, 2019, by and among Misonix, Inc., Allan Staley, Linwood Staub and Dr. Arti Masturzo.

Exhibit 10.1 EXECUTION VERSION SUPPORT AGREEMENT THIS SUPPORT AGREEMENT, dated as of May 2, 2019 (this “Agreement”), is entered into by and among Misonix, Inc., a New York corporation (“Motor”) and the undersigned signatories set forth on the signature pages hereto under the heading “Supporting Surge Unitholders” (collectively, the “Supporting Surge Unitholders”). Motor and the Supporting Surge Un

Form of Lock-Up Agreement

Exhibit 10.4 Form of Lock-Up Agreement May 2, 2019 New Misonix, Inc. 1938 New Highway Farmingdale, NY 11735 Re: New Misonix, Inc. Lock-Up Agreement Ladies and Gentlemen: The undersigned understands that New Misonix, Inc., a New York corporation and a direct, wholly owned subsidiary of Misonix, Inc. (“ParentCo”), has entered into an Agreement and Plan of Merger with Solsys Medical, LLC, a Delaware

Filed by Misonix, Inc.

Exhibit 99.1 Filed by Misonix, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14-a-12 of the Securities Exchange Act of 1934 Misonix, Inc. – Definitive Agreement to Acquire Solsys Medical, May 3, 2019 C O R P O R A T E P A R T I C I P A N T S Norberto Aja, Investor Relations, JCIR Stavros Vizirgianakis, President and Chief Executive Officer, Misonix, I

Support Agreement, dated May 2, 2019, by and among Misonix, Inc. 1315 Capital Solsys, Inc. and SV-Solsys Inc.

Exhibit 10.2 EXECUTION VERSION SUPPORT AGREEMENT THIS SUPPORT AGREEMENT, dated as of May 2, 2019 (this “Agreement”), is entered into by and among Misonix, Inc., a New York corporation (“Motor”) and the undersigned signatories set forth on the signature pages hereto under the heading “Supporting Surge Unitholders” (collectively, the “Supporting Surge Unitholders”). Motor and the Supporting Surge Un

Agreement and Plan of Merger, dated May 2, 2019, by and among Misonix, New Misonix, Inc., Reincorp. Merger Sub One, Inc., Surge Sub Two, LLC, Solsys and, solely in its capacity as the representative for the Solsys equityholders, Greg Madden (incorporated by reference to Exhibit 2.1 to the Old Misonix’s Current Report on Form 8-K filed May 6, 2019)

Exhibit 2.1 AGREEMENT AND PLAN OF MERGER among MISONIX, INC., NEW MISONIX, INC., MOTOR REINCORP. SUB ONE, INC., SURGE SUB TWO, LLC, SOLSYS MEDICAL, LLC, and GREG MADDEN, solely in his capacity as the Representative Dated as of May 2, 2019 TABLE OF CONTENTS Page ARTICLE 1. THE MERGERS 3 Section 1.1 Closing 3 Section 1.2 Reincorporation Merger 4 Section 1.3 Combination Merger 5 Section 1.4 Headquart

Support Agreement, dated May 2, 2019, by and among Misonix, Inc., Stavros Vizirgianakis, Joseph Dwyer, Sharon Klugewicz, Scott Ludecker, John Salerno and Dan Voic.

Exhibit 10.3 EXECUTION VERSION SUPPORT AGREEMENT THIS SUPPORT AGREEMENT, dated as of May 2, 2019 (this “Agreement”), is entered into by and among Misonix, Inc., a New York corporation (“Motor”) and the undersigned signatories set forth on the signature pages hereto under the heading “Supporting Motor Shareholders,” in their capacity as shareholders (and not, if applicable, as a director or officer

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 2, 2019 MISONIX, INC. (Exact name of Registrant as specified in its charter) New York 001-10986 11-2148932 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Filed by Misonix, Inc.

Exhibit 99.1 Filed by Misonix, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14-a-12 of the Securities Exchange Act of 1934 Misonix, Inc. – Definitive Agreement to Acquire Solsys Medical, May 3, 2019 C O R P O R A T E P A R T I C I P A N T S Norberto Aja, Investor Relations, JCIR Stavros Vizirgianakis, President and Chief Executive Officer, Misonix, I

Form of Lock-Up Agreement

Exhibit 10.4 Form of Lock-Up Agreement May 2, 2019 New Misonix, Inc. 1938 New Highway Farmingdale, NY 11735 Re: New Misonix, Inc. Lock-Up Agreement Ladies and Gentlemen: The undersigned understands that New Misonix, Inc., a New York corporation and a direct, wholly owned subsidiary of Misonix, Inc. (“ParentCo”), has entered into an Agreement and Plan of Merger with Solsys Medical, LLC, a Delaware

MSON / Misonix, Inc. 425 Merger Prospectus 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 2, 2019 MISONIX, INC. (Exact name of Registrant as specified in its charter) New York 001-10986 11-2148932 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Agreement and Plan of Merger, dated May 2, 2019, by and among Misonix, New Misonix, Inc., Reincorp. Merger Sub One, Inc., Surge Sub Two, LLC, Solsys and, solely in its capacity as the representative for the Solsys equityholders, Greg Madden.

Exhibit 2.1 AGREEMENT AND PLAN OF MERGER among MISONIX, INC., NEW MISONIX, INC., MOTOR REINCORP. SUB ONE, INC., SURGE SUB TWO, LLC, SOLSYS MEDICAL, LLC, and GREG MADDEN, solely in his capacity as the Representative Dated as of May 2, 2019 TABLE OF CONTENTS Page ARTICLE 1. THE MERGERS 3 Section 1.1 Closing 3 Section 1.2 Reincorporation Merger 4 Section 1.3 Combination Merger 5 Section 1.4 Headquart

Support Agreement, dated May 2, 2019, by and among Misonix, Inc. 1315 Capital Solsys, Inc. and SV-Solsys Inc.

Exhibit 10.2 EXECUTION VERSION SUPPORT AGREEMENT THIS SUPPORT AGREEMENT, dated as of May 2, 2019 (this “Agreement”), is entered into by and among Misonix, Inc., a New York corporation (“Motor”) and the undersigned signatories set forth on the signature pages hereto under the heading “Supporting Surge Unitholders” (collectively, the “Supporting Surge Unitholders”). Motor and the Supporting Surge Un

Support Agreement, dated May 2, 2019, by and among Misonix, Inc., Stavros Vizirgianakis, Joseph Dwyer, Sharon Klugewicz, Scott Ludecker, John Salerno and Dan Voic.

Exhibit 10.3 EXECUTION VERSION SUPPORT AGREEMENT THIS SUPPORT AGREEMENT, dated as of May 2, 2019 (this “Agreement”), is entered into by and among Misonix, Inc., a New York corporation (“Motor”) and the undersigned signatories set forth on the signature pages hereto under the heading “Supporting Motor Shareholders,” in their capacity as shareholders (and not, if applicable, as a director or officer

Support Agreement, dated May 2, 2019, by and among Misonix, Inc., Allan Staley, Linwood Staub and Dr. Arti Masturzo.

Exhibit 10.1 EXECUTION VERSION SUPPORT AGREEMENT THIS SUPPORT AGREEMENT, dated as of May 2, 2019 (this “Agreement”), is entered into by and among Misonix, Inc., a New York corporation (“Motor”) and the undersigned signatories set forth on the signature pages hereto under the heading “Supporting Surge Unitholders” (collectively, the “Supporting Surge Unitholders”). Motor and the Supporting Surge Un

MISONIX, INC. ENTERS INTO DEFINITIVE AGREEMENT TO ACQUIRE REGENERATIVE MEDICAL COMPANY SOLSYS MEDICAL FOR APPROXIMATELY $97 MILLION Transaction Creates Medical Device Company with Comprehensive Portfolio of Wound Care Solutions to Improve Healthcare

Exhibit 99.1 News Announcement MISONIX, INC. ENTERS INTO DEFINITIVE AGREEMENT TO ACQUIRE REGENERATIVE MEDICAL COMPANY SOLSYS MEDICAL FOR APPROXIMATELY $97 MILLION Transaction Creates Medical Device Company with Comprehensive Portfolio of Wound Care Solutions to Improve Healthcare Outcomes Combined Entity to Generate Over $80 Million in Annual Revenue for Fiscal 2020 FARMINGDALE, N.Y. (May 2, 2019)

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 2, 2019 MISONIX, INC. (Exact name of Registrant as specified in its charter) New York 001-10986 11-2148932 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Misonix –Vision for the Future

Exhibit 99.2 Misonix –Vision for the Future Forward Looking Statements This communication contains forward-looking statements, which address a variety of subjects including, for example, the expected timetable for closing of the transaction between Misonix and Solsys, the allocation of the merger consideration and the anticipated growth rate of the combined company. Statements that are not histori

MSON / Misonix, Inc. 425 Merger Prospectus 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 2, 2019 MISONIX, INC. (Exact name of Registrant as specified in its charter) New York 001-10986 11-2148932 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Misonix –Vision for the Future

EX-99.2 3 s117971ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Misonix –Vision for the Future Forward Looking Statements This communication contains forward-looking statements, which address a variety of subjects including, for example, the expected timetable for closing of the transaction between Misonix and Solsys, the allocation of the merger consideration and the anticipated growth rate of the combined

MISONIX, INC. ENTERS INTO DEFINITIVE AGREEMENT TO ACQUIRE REGENERATIVE MEDICAL COMPANY SOLSYS MEDICAL FOR APPROXIMATELY $97 MILLION Transaction Creates Medical Device Company with Comprehensive Portfolio of Wound Care Solutions to Improve Healthcare

Exhibit 99.1 News Announcement MISONIX, INC. ENTERS INTO DEFINITIVE AGREEMENT TO ACQUIRE REGENERATIVE MEDICAL COMPANY SOLSYS MEDICAL FOR APPROXIMATELY $97 MILLION Transaction Creates Medical Device Company with Comprehensive Portfolio of Wound Care Solutions to Improve Healthcare Outcomes Combined Entity to Generate Over $80 Million in Annual Revenue for Fiscal 2020 FARMINGDALE, N.Y. (May 2, 2019)

MSON / Misonix, Inc. DEF 14A

DEF 14A 1 s116834def14a.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as pe

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

8-K 1 s1163628k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 4, 2019 (March 1, 2019) MISONIX, INC. (Exact name of registrant as specified in its charter) New York 001-10986 11-2148932 (State or other jurisdiction o

Offer Letter dated February 6, 2019

Exhibit 10.1 February 6, 2019 Ms. Sharon Klugewicz 17 Roxbury Road Rockville, Centre 11570 Dear Sharon: It gives me great pleasure to offer “at will’ employment for the position of Chief Operating Officer. You will report to Stavros Vizirgianakis, President and Chief Executive Officer for your assignments. The base salary for this position will be $ 250,000 per annum, paid in twenty-four (24), sem

MISONIX NAMES SHARON KLUGEWICZ CHIEF OPERATING OFFICER Proven C-Suite Executive Brings Extensive Healthcare Industry Experience to New Role

Exhibit 99.1 News Announcement For Immediate Release MISONIX NAMES SHARON KLUGEWICZ CHIEF OPERATING OFFICER Proven C-Suite Executive Brings Extensive Healthcare Industry Experience to New Role FARMINGDALE, N.Y., (March 4, 2019) – Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical outcomes, today a

MISONIX FISCAL 2019 SECOND QUARTER REVENUE RISES 22% TO A RECORD $10.2 MILLION

Exhibit 99.1 MISONIX FISCAL 2019 SECOND QUARTER REVENUE RISES 22% TO A RECORD $10.2 MILLION FARMINGDALE, N.Y. (February 6, 2019) – Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical outcomes, today reported financial results for the fiscal 2019 second quarter ended December 31, 2018 as summarized

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2019 MISONIX, INC.

MSON / Misonix, Inc. FORM 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to .

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 22, 2019 MISONIX, INC.

MSON / Misonix, Inc. / South Africa Alpha Capital Management Ltd. Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Misonix, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 604871103 (CUSIP Number) December 31, 2018 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2018 MISONIX, INC.

MISONIX FISCAL 2019 FIRST QUARTER REVENUE RISES 29% TO RECORD $9.4 MILLION

Exhibit 99.1 MISONIX FISCAL 2019 FIRST QUARTER REVENUE RISES 29% TO RECORD $9.4 MILLION FARMINGDALE, N.Y., (November 8, 2018) – Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical outcomes, today reported financial results for the fiscal 2019 first quarter ended September 30, 2018 as summarized bel

MSON / Misonix, Inc. FORM 10Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to .

MSON / Misonix, Inc. FORM 10-K (Annual Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-10986 MISONIX, INC.

CORRECTING and REPLACING – MISONIX REPORTS RECORD FOURTH QUARTER AND FISCAL YEAR 2018 REVENUE Fiscal Year 2018 Revenue Rises 35% to $36.7 Million

Exhibit 99.2 CORRECTING and REPLACING – MISONIX REPORTS RECORD FOURTH QUARTER AND FISCAL YEAR 2018 REVENUE Fiscal Year 2018 Revenue Rises 35% to $36.7 Million (GLOBE NEWSWIRE) - On September 5, 2018, Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), issued a press release announcing financial results of its fourth fiscal quarter and fiscal year ended June 30, 2018. The sales performance s

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A (Amendment No.

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A (Amendment No.

MISONIX REPORTS RECORD FOURTH QUARTER AND FISCAL YEAR 2018 REVENUE Fiscal Year 2018 Revenue Rises 35% to $36.7 Million

Exhibit 99.1 MISONIX REPORTS RECORD FOURTH QUARTER AND FISCAL YEAR 2018 REVENUE Fiscal Year 2018 Revenue Rises 35% to $36.7 Million FARMINGDALE, N.Y., (September 5, 2018) – Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical outcomes, today reported financial results for the fiscal 2018 fourth quar

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 5, 2018 MISONIX, INC.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A (Amendment No.

MISONIX NAMES LEADING MEDICAL DEVICE EXECUTIVE GWEN WATANABE TO BOARD OF DIRECTORS Current Teleflex Incorporated Executive and Accomplished Industry Entrepreneur Brings Strategic Leadership and Deep Expertise with Growing Medical Device Companies to

Exhibit 99.1 News Announcement For Immediate Release MISONIX NAMES LEADING MEDICAL DEVICE EXECUTIVE GWEN WATANABE TO BOARD OF DIRECTORS Current Teleflex Incorporated Executive and Accomplished Industry Entrepreneur Brings Strategic Leadership and Deep Expertise with Growing Medical Device Companies to the Misonix Board FARMINGDALE, N.Y., (July 19, 2018) – Misonix, Inc. (NASDAQ: MSON) (“Misonix” or

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 18, 2018 MISONIX, INC.

MSON / Misonix, Inc. SD

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report MISONIX, INC. (Exact name of registrant as specified in its charter) New York 1-10986 11-2148932 (State or other jurisdiction of Incorporation or organization) (Commission File Number) (IRS Employer Identification No.) 1938 New Highway, Farmingdale, NY 11735 (Address of principal executive

Exhibit 1.01 - Conflict Minerals Report.

EXHIBIT 1.01 Conflict Minerals Report Misonix, Inc. (the “Company”) has determined that gold, tantalum, tin and/or tungsten (collectively, the “Minerals”), certain of the minerals covered by Rule 13p-1 promulgated under the Securities Exchange Act of 1934, as amended, are contained in circuit boards purchased by the Company as components for certain of the Company’s medical device products (the “P

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2018 MISONIX, INC.

MISONIX REPORTS RECORD THIRD QUARTER REVENUE Revenue Rises 73% to $12.4 Million, Inclusive of $4.0 Million in Licensing Revenue, Resulting in Record Quarterly Diluted EPS of $0.23

Exhibit 99.1 MISONIX REPORTS RECORD THIRD QUARTER REVENUE Revenue Rises 73% to $12.4 Million, Inclusive of $4.0 Million in Licensing Revenue, Resulting in Record Quarterly Diluted EPS of $0.23 FARMINGDALE, N.Y., (May 7, 2018) – Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical outcomes, today rep

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2018 MISONIX, INC.

10.21 Amendment No. 1 to License and Exclusive Manufacturing Agreement dated February 26, 2018 between Misonix, Inc. and Hunan Xing Hang Rui Kang Bio-technologies Co. Ltd (26)

Exhibit 10.1 AMENDMENT NO. 1 TO LICENSE AND EXCLUSIVE MANUFACTURING AGREEMENT This AMENDMENT NO. 1 TO LICENSE AND EXCLUSIVE MANUFACTURING AGREEMENT is entered into on the 26 day of February, 2018, by and between Misonix, Inc., a New York corporation, with offices at 1938 New Highway, Farmingdale, New York 11735 USA (“Misonix”), and Hunan Xing Hang Rui Kang Bio-technologies Co., Ltd. a Chinese corp

MSON / Misonix, Inc. 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to .

MSON / Misonix, Inc. S-3/A

As filed with the Securities and Exchange Commission on April 24, 2018 Registration No.

MSON / Misonix, Inc. CORRESP

MISONIX, INC. 1938 New Highway Farmingdale, NY 11735 631-694-9555 (Phone) April 19, 2018 Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street NE Washington, DC 20549 Re: MISONIX, INC. (the “Company”) Registration Statement on Form S-3 (File No. 333-223878) Ladies and Gentlemen: In connection with the above-captioned Registration Statement, the Company hereby request

MSON / Misonix, Inc. CORRESP

MISONIX, INC. 1938 New Highway Farmingdale, NY 11735 631-694-9555 (Phone) April 9, 2018 VIA EDGAR Mr. Martin James Senior Assistant Chief Accountant United States Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Re: Misonix, Inc. Form 10-K for the Fiscal Year Ended June 30, 2017 Filed August 24, 2017 Form 10-Q for the Quarterly Period Ended December 31, 2017 Filed Februar

Power of Attorney (included on the signature page of the Registration Statement)

S-3 1 s109347s-3.htm S-3 As filed with the Securities and Exchange Commission on March 23, 2018 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MISONIX, INC. (Exact name of registrant as specified in its charter) New York 11-2148932 (State or other jurisdiction of incorporation or organizat

MSON / Misonix, Inc. DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin

MSON / Misonix, Inc. PRE 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin

MSON / Misonix, Inc. / South Africa Alpha Capital Management Ltd. Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Misonix, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 604871103 (CUSIP Number) December 31, 2017 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu

MSON / Misonix, Inc. / DIMENSIONAL FUND ADVISORS LP - SCHEDULE 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 10)* MISONIX INC (Name of Issuer) Common Stock (Title of Class of Securities) 604871103 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule i

MISONIX REPORTS RECORD SECOND QUARTER REVENUE - Continued Strong Sales of BoneScalpel and SonaStar Product Lines Drive Overall 38% Revenue Growth -

Exhibit 99.1 MISONIX REPORTS RECORD SECOND QUARTER REVENUE - Continued Strong Sales of BoneScalpel and SonaStar Product Lines Drive Overall 38% Revenue Growth - FARMINGDALE, N.Y., (February 6, 2018) ? Misonix, Inc. (Nasdaq: MSON) (?Misonix? or the ?Company?), a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical outcomes, today reported financial results for

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2018 MISONIX, INC.

10.20 License and Exclusive Manufacturing Agreement between Misonix, Inc. and Hunan Xing Hang Rui Kang Bio-technologies Co. Ltd (confidential treatment has been granted for portions of this exhibit) (25)

Exhibit 10.1 LICENSE AND EXCLUSIVE MANUFACTURING AGREEMENT This License and Exclusive Manufacturing Agreement (the “Agreement”) is entered into on the 21st day of August, 2017 (the “Effective Date”), by and between Misonix, Inc., a New York corporation, with offices at 1938 New Highway, Farmingdale, New York 11735 USA (“Misonix”), and Hunan Xing Hang Rui Kang Bio-technologies Co., Ltd. a Chinese c

December 31, 2017

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to .

JOINT FILING AGREEMENT

Exhibit 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of November 24, 2017, is by and among South Africa Alpha Capital Management Ltd. and Praesidium Capital Management (Pty) Ltd (collectively, the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commission a statement on Schedule 13D and/or 13G with respect to the Common Stoc

MSON / Misonix, Inc. / South Africa Alpha Capital Management Ltd. Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Misonix, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 604871103 (CUSIP Number) October 20, 2017 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan

Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2017 MISONIX, INC.

Letter from Grant Thornton LLP addressed to the Securities and Exchange Commission dated November 13, 2017

Exhibit 16.1 November 13, 2017 U.S. Securities and Exchange Commission Office of the Chief Accountant 100 F Street, NE Washington, DC 20549 Grant Thornton LLP 75 State Street, 13th Floor Boston, MA 02109-1827 T 617.723.7900 F 617.723.3640 GrantThornton.com linkd.in/GrantThorntonUS twitter.com/GrantThorntonUS Re: MISONIX, INC. File No. 1-10986 Dear Sir or Madam: We have read Item 4.01 of Form 8-K o

Misonix Reports First Quarter Fiscal Year 2018 Financial Results Corporate Contact Investor Contact Joe Dwyer Joe Diaz Misonix, Inc. Lytham Partners 631-927-9113 602-889-9700 [email protected] [email protected]

Exhibit 99.1 Misonix Reports First Quarter Fiscal Year 2018 Financial Results For Immediate Release Corporate Contact Investor Contact Joe Dwyer Joe Diaz Misonix, Inc. Lytham Partners 631-927-9113 602-889-9700 [email protected] [email protected] FARMINGDALE, NY ? November 7, 2017 - Misonix, Inc. (Nasdaq: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices that enh

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2017 MISONIX, INC.

September 30, 2017

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to .

Misonix Enters into $11 Million License, Royalty and Manufacturing Agreement

Exhibit 99.1 Misonix Enters into $11 Million License, Royalty and Manufacturing Agreement For Immediate Release Corporate Contact Investor Contact Joe Dwyer Joe Diaz Misonix, Inc. Lytham Partners 631-927-9113 602-889-9700 [email protected] [email protected] FARMINGDALE, NY ? October 20, 2017 - Misonix, Inc. (Nasdaq: MSON), a provider of minimally invasive therapeutic ultrasonic medical devi

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 19, 2017 MISONIX, INC.

Amendment dated as of September 18, 2017 to letter agreement between the Company and Richard A. Zaremba

Exhibit 10.1 September 18, 2017 Mr. Richard A. Zaremba c/o MISONIX, INC. 1938 New Highway Farmingdale, New York 11735 Dear Richard: This letter will serve to modify the letter agreement dated September 15, 2016 (which amended and restated a prior letter agreement dated November 14, 2011) (collectively, the ?Original Letter Agreement?), by and between you and MISONIX, INC. (?Misonix?). To the exten

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2017 MISONIX, INC.

Form 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-10986 MISONIX, INC.

Subsidiaries of the Company.

Exhibit 21 Subsidiaries of the Company 1. Misonix Limited, a United Kingdom corporation 2. Fibra-Sonics (NY) Inc., a New York corporation 3. Hearing Innovations, Incorporated, a Delaware corporation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 21, 2017 MISONIX, INC.

Misonix Appoints Joseph Dwyer as Chief Financial Officer

Exhibit 99.1 Misonix Appoints Joseph Dwyer as Chief Financial Officer For Immediate Release Corporate Contact Investor Contact Joe Dwyer Joe Diaz Misonix, Inc. Lytham Partners 631-927-9113 602-889-9700 [email protected] [email protected] FARMINGDALE, NY ? August 23, 2017 - Misonix, Inc. (Nasdaq: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clin

10.19 Employment Agreement dated August 21, 2017 between the Company and Joseph P. Dwyer (24)

Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this ?Agreement?) is entered into on August 21, 2017 (the ?Effective Date?) by and between MISONIX, INC., a New York corporation, with principal offices at 1938 New Highway, Farmingdale, New York 11735 (?Employer?), and JOSEPH P. DWYER, with an address at 3 Cordwood Court, East Northport, New York 11731 (?Executive?). WHEREAS, Employer i

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 22, 2017 MISONIX, INC.

Misonix Reports Fiscal Year 2017 Financial Results Corporate Contact Investor Contact Joe Dwyer Joe Diaz Misonix, Inc. Lytham Partners 631-927-9113 602-889-9700 [email protected] [email protected]

Exhibit 99.1 Misonix Reports Fiscal Year 2017 Financial Results For Immediate Release Corporate Contact Investor Contact Joe Dwyer Joe Diaz Misonix, Inc. Lytham Partners 631-927-9113 602-889-9700 [email protected] [email protected] FARMINGDALE, NY ? August 22, 2017 - Misonix, Inc. (Nasdaq: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical o

2017 Equity Incentive Plan (16)

Exhibit 99.1 MISONIX, INC. 2017 EQUITY INCENTIVE PLAN Section 1. Purpose. The purposes of this Misonix, Inc. 2017 Equity Incentive Plan (the ?Plan?) are (1) to make available to key employees, directors and consultants certain compensatory arrangements related to the growth in value of the common stock of the Company so as to generate an increased incentive to contribute to the Company?s future fi

Misonix S-8

S-8 1 s106826s8.htm S-8 As filed with the Securities and Exchange Commission on July 19, 2017 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MISONIX, INC. (Exact name of registrant as specified in its charter) New York 11-2148932 (State or other jurisdiction of (IRS Employer incorporation

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2017 MISONIX, INC.

Misonix SD

SD 1 s106313sd.htm SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report MISONIX, INC. (Exact name of registrant as specified in its charter) New York 1-10986 11-2148932 (State or other jurisdiction of (Commission File Number) (IRS Employer Incorporation or organization) Identification No.) 1938 New Highway, Farmingdale, NY 11735 (Address

Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form.

EXHIBIT 1.01 Conflict Minerals Report Misonix, Inc. (the ?Company?) has determined that gold, tantalum, tin and/or tungsten (collectively, the ?Minerals?), certain of the minerals covered by Rule 13p-1 promulgated under the Securities Exchange Act of 1934, as amended, are contained in circuit boards purchased by the Company as components for certain of the Company?s medical device products (the ?P

Misonix 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to .

Misonix 8-K (Current Report/Significant Event)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2017 MISONIX, INC.

Misonix Reports Third Quarter Fiscal Year 2017 Financial Results Corporate Contact Investor Contact Joe Dwyer Joe Diaz Misonix, Inc. Lytham Partners 631-927-9113 602-889-9700 [email protected] [email protected]

Exhibit 99.1 Misonix Reports Third Quarter Fiscal Year 2017 Financial Results For Immediate Release Corporate Contact Investor Contact Joe Dwyer Joe Diaz Misonix, Inc. Lytham Partners 631-927-9113 602-889-9700 [email protected] [email protected] FARMINGDALE, NY ? May 2, 2017 - Misonix, Inc. (Nasdaq: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices that enhance

Misonix DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2017 MISONIX, INC.

Misonix Files Forms 10-Q for First and Second Quarters of Fiscal 2017 Regains full compliance with SEC and Nasdaq requirements and increases six-months sales of consumable products by 29.4% Corporate Contact Investor Contact Joe Dwyer Joe Diaz Misoni

Exhibit 99.1 Misonix Files Forms 10-Q for First and Second Quarters of Fiscal 2017 Regains full compliance with SEC and Nasdaq requirements and increases six-months sales of consumable products by 29.4% For Immediate Release Corporate Contact Investor Contact Joe Dwyer Joe Diaz Misonix, Inc. Lytham Partners 631-927-9113 602-889-9700 [email protected] [email protected] FARMINGDALE, NY ? Marc

Misonix 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2016 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to .

Misonix 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2016 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to .